WallStSmart

Bioceres Crop Solutions Corp (BIOX)vsCorteva Inc (CTVA)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Corteva Inc generates 1989% more annual revenue ($4.97B vs $237.80M). CTVA leads profitability with a 2.8% profit margin vs -19.7%. CTVA appears more attractively valued with a PEG of 1.05. BIOX earns a higher WallStSmart Score of 46/100 (D+).

BIOX

Hold

46

out of 100

Grade: D+

Growth: 4.7Profit: 2.0Value: 4.7Quality: 3.3
Piotroski: 2/9

CTVA

Hold

45

out of 100

Grade: D+

Growth: 2.0Profit: 5.0Value: 7.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.49
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BIOX.

CTVAUndervalued (+7.4%)

Margin of Safety

+7.4%

Fair Value

$12.56

Current Price

$11.47

$1.09 discount

UndervaluedFair: $12.56Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BIOX2 strengths · Avg: 9.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

EPS GrowthGrowth
34.4%8/10

Earnings expanding 34.4% YoY

CTVA3 strengths · Avg: 9.7/10
P/E RatioValuation
8.0x10/10

Attractively priced relative to earnings

Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

Areas to Watch

BIOX4 concerns · Avg: 3.0/10
PEG RatioValuation
1.954/10

Expensive relative to growth rate

Market CapQuality
$16.28M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-359.8%2/10

ROE of -359.8% — below average capital efficiency

CTVA4 concerns · Avg: 2.5/10
Return on EquityProfitability
4.0%3/10

ROE of 4.0% — below average capital efficiency

Profit MarginProfitability
2.8%3/10

2.8% margin — thin

Revenue GrowthGrowth
-1.2%2/10

Revenue declined 1.2%

EPS GrowthGrowth
-9.9%2/10

Earnings declined 9.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : BIOX

The strongest argument for BIOX centers on Price/Book, EPS Growth.

Bull Case : CTVA

The strongest argument for CTVA centers on P/E Ratio, Price/Book, Debt/Equity. PEG of 1.05 suggests the stock is reasonably priced for its growth.

Bear Case : BIOX

The primary concerns for BIOX are PEG Ratio, Market Cap, Piotroski F-Score. Debt-to-equity of 6.06 is elevated, increasing financial risk.

Bear Case : CTVA

The primary concerns for CTVA are Return on Equity, Profit Margin, Revenue Growth. Thin 2.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

BIOX profiles as a turnaround stock while CTVA is a value play — different risk/reward profiles.

CTVA carries more volatility with a beta of 0.58 — expect wider price swings.

CTVA is growing revenue faster at -1.2% — sustainability is the question.

Monitor AGRICULTURAL INPUTS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BIOX scores higher overall (46/100 vs 45/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bioceres Crop Solutions Corp

BASIC MATERIALS · AGRICULTURAL INPUTS · USA

Bioceres Crop Solutions Corp.

Corteva Inc

BASIC MATERIALS · AGRICULTURAL INPUTS · USA

Corteva, Inc. (also known as Corteva Agriscience) is a major American agricultural chemical and seed company that was the agricultural unit of DowDuPont prior to being spun off as an independent public company.

Visit Website →

Want to dig deeper into these stocks?